Coherus Oncology Net Current Debt 2013-2025 | CHRS

Coherus Oncology net current debt from 2013 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.

Coherus Oncology Net Current Debt 2013-2025 | CHRS

Coherus Oncology net current debt from 2013 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.5B
Amgen (AMGN)$165.9B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$99.6B
CSL (CSLLY)$86.2B
GSK (GSK)$78.3B
Regeneron Pharmaceuticals (REGN)$61B
Alnylam Pharmaceuticals (ALNY)$42.8B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.4B
Illumina (ILMN)$17B
Genmab (GMAB)$15.2B
Genmab (GNMSF)$14.9B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.5B
QIAGEN (QGEN)$11.4B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.2B
Bio-Techne Corp (TECH)$9.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B